会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • SCSI bus transceiver and method for making the same
    • SCSI总线收发器及其制作方法
    • US06173344B2
    • 2001-01-09
    • US09085671
    • 1998-05-27
    • Abdul Waheed MohammedPeter K. CheungBarry DavisChristopher Burns
    • Abdul Waheed MohammedPeter K. CheungBarry DavisChristopher Burns
    • G06F1300
    • G06F13/4072
    • Disclosed is a SCSI host adapter for use in a computer system. The SCSI host adapter is configured to provide the computer system with interconnection with internal and/or external target devices. The SCSI host adapter includes a low voltage differential connector for interconnecting to a low voltage differential bus, and the low voltage differential bus is configured to communicate a first transaction. The SCSI host adapter also includes a single ended connector for interconnecting to a single ended bus, and the single ended bus is configured to communicate a second transaction. Furthermore, the SCSI host adapter includes a transceiver unit that is configured to interface between the low voltage differential bus and the single ended bus and produce a target information signal. The target information signal is configured to indicate whether the first transaction or the second transaction is occurring between the SCSI host adapter and the low voltage differential bus or the single ended bus.
    • 公开了一种用于计算机系统的SCSI主机适配器。 SCSI主机适配器被配置为向计算机系统提供与内部和/或外部目标设备的互连。 SCSI主机适配器包括用于互连到低电压差分总线的低压差分连接器,并且低电压差分总线被配置为传送第一事务。 SCSI主机适配器还包括用于互连到单端总线的单端连接器,并且单端总线被配置为传送第二事务。 此外,SCSI主机适配器包括收发器单元,其被配置为在低电压差分总线和单端总线之间进行接口并产生目标信息信号。 目标信息信号被配置为指示在SCSI主机适配器和低电压差分总线或单端总线之间是否发生第一事务或第二事务。
    • 8. 发明授权
    • Farnesyl transferase inhibitors, preparation thereof and pharmaceuticals
compositions containing said inhibitors
    • 法呢基转移酶抑制剂,其制备物和含有所述抑制剂的药物组合物
    • US5889053A
    • 1999-03-30
    • US5154
    • 1998-01-09
    • Bernard BaudoinChristopher BurnsAlain CommerconAlain Lebrun
    • Bernard BaudoinChristopher BurnsAlain CommerconAlain Lebrun
    • A61K31/195A61K31/215A61P35/00A61P43/00C07C323/59A61K31/235
    • C07C323/59
    • Novel farnesyl transferase inhibitors of general formula (I), ##STR1## the preparation thereof and pharmaceutical compositions containing said inhibitors, are disclosed. In general formula (I), R.sub.1 is Y--S--A.sub.1 (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical or a radical R.sub.4 --S-- where R.sub.4 is a C.sub.1-4 alkyl radical optionally substituted by a phenyl radical or a radical of general formula (II) ##STR2## wherein A.sub.1, X, X.sub.1, Y.sub.1, R'.sub.1, R.sub.2, R'.sub.2 and R are defined as below, and A.sub.1 is a C.sub.1-4 alkylene radical optionally alpha-substituted in the >C(X.sub.1)(Y.sub.1) grouping by an amino or alkylamino, dialkylamino, alkanoylamino or alkoxycarbonylamino radical); X.sub.1 and Y.sub.1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, form a >C.dbd.O grouping; R'.sub.1 is hydrogen or a C.sub.1-6 alkyl radical; X is an oxygen or sulphur atom; R.sub.2 is a C.sub.1-6 alkyl, alkenyl or alkynyl radical optionally substituted by hydroxyl, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl, with the proviso that when R.sub.2 is an alkyl radical substituted by a hydroxy radical, R.sub.2 can form a lactone with the .alpha.-carboxy radical; and R'.sub.2 is hydrogen or a C.sub.1-6 alkyl radical; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted pheny radical, with the proviso that radical (a) ##STR3## is in the 3 or 4 position of the naphthyl ring. The novel products have anticancer properties.
    • 公开了通式(I)的新型法呢基转移酶抑制剂,其制备方法和含有所述抑制剂的药物组合物。 在通式(I)中,R 1是YS-A1(其中Y是氢原子,氨基酸残基,脂肪酸残基,烷基或烷氧基羰基或基团R 4 -S-,其中R 4是C 1-4烷基 任选被苯基或通式(II)的基团取代的基团其中A1,X,X1,Y1,R'1,R2,R'2和R定义如下,而A1是 通过氨基或烷基氨基,二烷基氨基,烷酰基氨基或烷氧基羰基氨基,在> C(X1)(Y1)组中任意α-取代的C1-4亚烷基; X1和Y1各自为氢原子,或与它们所连接的碳原子一起形成> C = O基团; R 1是氢或C 1-6烷基; X是氧或硫原子; R2是任选被羟基,烷氧基,巯基,烷硫基,烷基亚磺酰基或烷基磺酰基取代的C 1-6烷基,烯基或炔基,条件是当R 2是被羟基取代的烷基时,R 2可以与 α-羧基; 和R'2是氢或C 1-6烷基; 并且R是氢原子或任选取代的烷基或任选取代的苯基,条件是基团(a)(a)在萘环的3或4位。 新产品具有抗癌性能。